Cortigiani L, Carpeggiani C, Landi P, Raciti M, Bovenzi F, Picano E Usefulness of Blunted Heart Rate Reserve as an Imaging-Independent Prognostic Predictor During Dipyridamole Stress Echocardiography. Am J Cardiol. 2019 Sep 15;124(6):972-977. doi: 10.1016/j.amjcard.2019.06.017. Epub 2019 Jun 26.
Cortigiani L, Rigo F, Gherardi S, Galderisi M, Sicari R, Picano E Prognostic implications of coronary flow reserve on left anterior descending coronary artery in hypertrophic cardiomyopathy. Am J Cardiol. 2008 Dec 15;102(12):1718-23. doi: 10.1016/j.amjcard.2008.08.023. Epub 2008 Oct 9.
Coumbe BGT, Groarke JD Cardiovascular Autonomic Dysfunction in Patients with Cancer. Curr Cardiol Rep. 2018 Jul 3;20(8):69. doi: 10.1007/s11886-018-1010-y. Review.
Pellikka PA, Arruda-Olson A, Chaudhry FA, Chen MH, Marshall JE, Porter TR, Sawada SG Guidelines for Performance, Interpretation, and Application of Stress Echocardiography in Ischemic Heart Disease: From the American Society of Echocardiography. J Am Soc Echocardiogr. 2020 Jan;33(1):1-41.e8. doi: 10.1016/j.echo.2019.07.001. Epub 2019 Nov 15.
Tadic M, Cuspidi C, Hering D, Venneri L, Grozdic-Milojevic I Radiotherapy-induced right ventricular remodelling: The missing piece of the puzzle. Arch Cardiovasc Dis. 2017 Feb;110(2):116-123. doi: 10.1016/j.acvd.2016.10.003. Epub 2017 Jan 20. Review.
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.